Improving the clinical accuracy and flexibility of the Alkaptonuria severity score index.

Alkaptonuria composite measure disease progression nitisinone resource‐limited

Journal

JIMD reports
ISSN: 2192-8304
Titre abrégé: JIMD Rep
Pays: United States
ID NLM: 101568557

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 28 01 2022
revised: 31 03 2022
accepted: 04 04 2022
entrez: 13 7 2022
pubmed: 14 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Alkaptonuria (AKU) is a rare genetic disorder where oxidised homogentisic acid accumulates in connective tissues, leading to multisystem disease. The clinical evaluation Alkaptonuria Severity Score Index (cAKUSSI) is a composite score that assesses the extent of AKU disease. However, some components assess similar disease features, are difficult to measure reliably or cannot be measured in resource-limited environments. cAKUSSI data from the 4-year SONIA 2 randomised controlled trial, which investigated nitisinone treatment in adults with AKU, were analysed (

Identifiants

pubmed: 35822087
doi: 10.1002/jmd2.12290
pii: JMD212290
pmc: PMC9259391
doi:

Types de publication

Journal Article

Langues

eng

Pagination

361-370

Informations de copyright

© 2022 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.

Déclaration de conflit d'intérêts

Harriet E. O. Cant, Iro Chatzidaki and Lucy A. Eddowes are employees of Costello Medical. Birgitta Olsson and Mattias Rudebeck were shareholders of Sobi at the time of these analyses, and were employees of Sobi at the initiation of these analyses. In the last 5 years, Lakshminarayan R. Ranganath has received honoraria and consulting fees from Sobi. Jean Baptiste Arnoux and Richard Imrich declare that they have no conflict of interest.

Références

J Inherit Metab Dis. 2021 May;44(3):666-676
pubmed: 33452825
J Inherit Metab Dis. 2011 Dec;34(6):1153-62
pubmed: 21744089
JIMD Rep. 2020 Jun 22;55(1):75-87
pubmed: 32904992
Arthritis Rheum. 2011 Dec;63(12):3887-96
pubmed: 22127706
Biochim Biophys Acta. 1969 Feb 18;177(1):94-105
pubmed: 4976426
Lancet. 1992 Oct 3;340(8823):813-7
pubmed: 1383656
N Engl J Med. 2002 Dec 26;347(26):2111-21
pubmed: 12501223
JIMD Rep. 2021 Nov 11;63(1):80-92
pubmed: 35028273
J Inherit Metab Dis. 2016 Mar;39(2):203-10
pubmed: 26596578
JIMD Rep. 2018;41:53-62
pubmed: 29654544
Med Chir Trans. 1902;85:69-78
pubmed: 20896987
Mol Genet Metab Rep. 2020 Apr 16;23:100588
pubmed: 32322505
Lancet Diabetes Endocrinol. 2020 Sep;8(9):762-772
pubmed: 32822600

Auteurs

Harriet E O Cant (HEO)

Costello Medical London UK.

Birgitta Olsson (B)

Garriguella AB Ekerö Sweden.

Mattias Rudebeck (M)

OnPoint Science AB Stockholm Sweden.

Jean-Baptiste Arnoux (JB)

Hôpital Necker-Enfants Malades Paris France.

Richard Imrich (R)

Institute of Clinical and Translational Research Biomedical Research Centre, Slovak Academy of Sciences Bratislava Slovakia.
National Institute of Rheumatic Diseases Piešťany Slovakia.

Lucy A Eddowes (LA)

Costello Medical London UK.

Lakshminarayan R Ranganath (LR)

Department of Clinical Biochemistry and Metabolic Medicine Liverpool University Hospitals NHS Foundation Trust Liverpool UK.
Institute of Ageing and Chronic Disease University of Liverpool Liverpool UK.

Classifications MeSH